Matt McIlwain

Overview

Matt McIlwain is a Managing Director at Madrona Venture Group, a Seattle-based venture capital firm. With over 25 years of experience in venture investing, he has been instrumental in supporting early-stage technology companies, particularly those leveraging applied machine learning and cloud computing. His investment focus spans sectors such as enterprise software, biotechnology, and the intersection of life sciences and data science. Under his leadership, Madrona has invested in a diverse portfolio of companies, including A-Alpha Bio, Amperity, Booster, Ozette, Qumulo, Read.ai, and Terraclear. Notably, he has been involved in investments that led to successful IPOs, such as Accolade, Apptio, Isilon, Nautilus, and Smartsheet. Additionally, McIlwain has contributed to the growth of companies acquired by major corporations, including ExtraHop (acquired by Bain/Crosspoint), Farecast (acquired by Microsoft), and Turi (acquired by Apple). Beyond his investment activities, McIlwain is actively engaged in nonprofit organizations. He has served on the board of directors for the Fred Hutchinson Cancer Research Center and the Washington Policy Center. His commitment to community and innovation is further demonstrated through his involvement in initiatives like the Intelligent Applications 40, which recognizes leading companies and trends in applied AI and intelligent applications. McIlwain holds a Bachelor of Arts from Dartmouth College, an MBA from Harvard Business School, and a Master in Public Policy from Harvard's Kennedy School of Government.

Investment Focus

• Strong founding team
• Innovative technology
• Scalable business model
• Clear market differentiation
• Potential for significant impact

Portfolio Companies